A recently identified RSK–LARG–ROCK pathway suggests that in glioma cells, RSK may also inhibit MYPT1 and promote motility through phosphorylation and activation of the LARG RhoGEF, which increases RhoA activation (84). Here, RPS6KA3 is linked to glioma.